Keyword: AbbVie

The days without biosimilar competition are numbered for AbbVie’s Humira in the U.S.—and that’s where rheumatoid arthritis drug Rinvoq comes in.

Skyrizi was the first IL-23 drug for psoriasis to hit after Johnson & Johnson's Tremfya and Sun Pharma's Ilumya.

AbbVie’s second entry on this list is Rova-T, an antibody-drug conjugate that finally outstayed its welcome after flunking a phase 3 study in small-cell lung cancer, a difficult-to-treat cancer linked to smoking.

High-grade gliomas are one of the toughest tumors to treat, and the first entrant on our alphabetical list—AbbVie’s antibody-drug conjugate Depatux-M—is one of at least three drugs that failed to hit the mark in this highly aggressive form of brain cancer in 2019.

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.